LIFESTYLE
[Iclickart] SEOUL -- South Korean state auditors sounded an alarm bell against the consistent consumption of Cetacean meat, which has been traded with no proper safety management or inspection of heavy metals and other hazardous materials. Hunting is banned in South Korea, but whales face threats from by-catch and pollution. The greatest threat of accidental death is stow nets used widely by fishermen who are allowed to keep and sell whales accidentally trapped in nets. Hundreds of
Jeju Governor Won Hee-ryong announces conditional approval of the Greenland International Hospital. [Yonhap News Photo] SEOUL -- South Korea's first for-profit hospital built by a Chinese investor on the southern resort island of Jeju was given the green light to start its delayed business only for foreigners despite protests by civic groups. On Wednesday, Jeju Governor Won Hee-ryong announced conditional approval of Greenland International Hospital. Won said the hospital with
[Celltrion] SEOUL -- South Korea's leading biosimilar manufacturer, Celltrion, has developed a subcutaneous injection of Remsima, a copy of Janssen Biotech's Remicade treating rheumatoid arthritis and Crohn's disease, to enhance patient convenience and access to medical care. Celltrion said Monday that Remsima SC has applied for approval by the European Medicines Agency. Instead of an intravenous injection that takes more than two hours in hospital, patients can inject
[Courtesy of Chong Kun Dang] SEOUL -- CKD-11101, a biosimilar developed by South Korea's pharmaceutical company Chong Kun Dang has won regulatory approval at home to sell the world's first copycat of Nesp for the treatment of anemia of chronic disease associated with cancer. Chong Kun Dang said the Ministry of Food and Drug Safety has approved CKD-11101. Marketing is possible in South Korea next year. It is the world's first biosimilar referencing Nesp codeveloped by
[Courtesy Celltrion] SEOUL -- Shares of South Korea's leading biosimilar manufacturer, Celltrion, rose sharply in early trading after its anti-cancer biosimilar, Truxima, was approved by the Food and Drug Administration (FDA) for sales in the United States. Truxima, which is already popular in Europe to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis, won FDA's approval as the first biosimilar to Rituxan (rituximab) manu
